Discussion by HMPC Drafting Group on Quality February Start of public consultation 27 June 2012

Similar documents
Discussion by HMPC Drafting Group on Quality September Start of public consultation 15 February 2013

European Medicines Agency COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Draft agreed by HMPC Quality Drafting Group October Adopted by HMPC 12 November 2013

Guideline on quality of herbal medicinal products 2 /traditional herbal medicinal products

Guideline on quality of herbal medicinal products 1 /traditional herbal medicinal products

Discussion at the HMPC January March Draft agreed by Quality Working Party April Adoption by CHMP for release for consultation 26 May 2005

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

HERBAL MEDICINES: Product Licence To Traditional Herbal Registration in the UK. Presented by: Mariam Aslam

REGULATION concerning Marketing Authorisations for Natural Medicinal Products and Registration of Traditional Herbal Medicinal Products, No. 142/2011.

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL PROCEDURE FOR THE PREPARATION OF COMMUNITY MONOGRAPHS FOR TRADITIONAL HERBAL MEDICINAL PRODUCTS

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., HERBA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Organisations and/or individuals

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON EQUISETUM ARVENSE L., HERBA

Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products 1

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Community herbal monograph on Olea europaea L., folium

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SOLIDAGO VIRGAUREA L., HERBA

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

European Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON PASSIFLORA INCARNATA L., HERBA

QUALITY OF HERBAL MEDICINAL PRODUCTS: PRESENT REQUIREMENTS

Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals

QUALITY OF HERBAL REMEDIES

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON BETULA PENDULA ROTH; BETULA PUBESCENS EHRH.

Community herbal monograph on Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne or their mixtures, flos

Community herbal monograph on Agropyron repens (L.) P. Beauv., rhizoma

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Community herbal monograph on Viola tricolor L. and/or subspecies Viola arvensis Murray (Gaud) and Viola vulgaris Koch (Oborny), herba cum flore

Community herbal monograph on Syzygium aromaticum (L.) Merill et L. M. Perry, floris aetheroleum

Overview of comments received on Community herbal monograph on Cucurbita pepo L, semen (EMA/HMPC/136024/2010)

Community herbal monograph on Olea europaea L., folium. November 2009 list (MLWP)

Community herbal monograph on Cinnamomum verum J.S. Presl (Cinnamomum zeylanicum Nees), aetheroleum

Agreed by Gastroenterology Drafting Group May Adopted by CHMP for release for consultation 24 May Start of public consultation 8 June 2012

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON

list (MLWP) September 2009 January 2010

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON RUSCUS ACULEATUS L., RHIZOMA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Procedural advice on publication of information on withdrawals of applications related to the marketing authorisation of human medicinal products

Community herbal monograph on Eucalyptus globulus Labill., folium

Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON THYMUS VULGARIS L. AND THYMUS ZYGIS L., HERBA

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ECHINACEA PALLIDA (NUTT.) NUTT., RADIX

Prof.Dr.Theodor Dingermann, Institut für Pharmazeutische Biologie, Goethe-Universität Frankfurt a.m.

Community herbal monograph on Cynara scolymus L., folium

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

Potential Grounds for Revocation of a Traditional Herbal Registration

European Medicines Agency Evaluation of Medicines for Human Use. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL

Guideline on the demonstration of palatability of veterinary medicinal products

Community herbal monograph on Agrimonia eupatoria L., herba

Good pharmacopoeial practices: Chapter on monographs on herbal medicines

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON MELILOTUS OFFICINALIS (L.) LAM., HERBA

Community herbal monograph on Fraxinus excelsior L. and Fraxinus angustifolia Vahl, folium

OVERVIEW OF COMMENTS RECEIVED ON COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM (EMEA/HMPC/114586/2008)

Community herbal monograph on Achillea millefolium L., flos

Community herbal monograph on Paullinia cupana Kunth ex H.B.K. var. sorbilis (Mart.) Ducke, semen

End of consultation (deadline for comments) 15 August 2012 Rediscussion in Working Party on Community monographs and Community list (MLWP)

Community herbal monograph on Cichorium intybus L., radix

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON ALTHAEA OFFICINALIS L., RADIX

Community herbal monograph on Rhodiola rosea L., rhizoma et radix

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON ROSMARINUS OFFICINALIS L., AETHEROLEUM

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Questions & answers on quality of herbal medicinal products/traditional herbal medicinal products 1

Overview of comments received on Community herbal monograph on Leonurus cardiaca L., herba (EMA/HMPC/561942/2010)

Community herbal monograph on Aesculus hippocastanum L., cortex

Community herbal monograph on Symphytum officinale L., radix

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON VALERIANA OFFICINALIS L., RADIX AND HUMULUS LUPULUS L.

Overview of comments on draft Reflection paper on level of purification of extracts to be considered as herbal preparations (EMEA/HMPC/186645/2008)

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) DRAFT COMMUNITY HERBAL MONOGRAPH ON ILEX PARAGUARIENSIS ST. HIL., FOLIUM

Particular challenges of evaluation of herbal combination products

European Medicines Agency. Superseded COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON SALVIA OFFICINALIS L.

Community herbal monograph on Levisticum officinale Koch, radix

Community herbal monograph on Marrubium vulgare L., herba

Community herbal monograph on Rosa gallica L., Rosa centifolia L., Rosa damascena Mill., flos

Superseded. Community herbal monograph on Ribes nigrum L., folium. Adoption by Committee on Herbal Medicinal Products (HMPC) 6 May 2010

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

1 March 2010 EMA/131300/2010 Human Medicines Development and Evaluation. 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom

Guideline on influenza vaccines submission and procedural requirements

European Medicines Agency decision

European Medicines Agency decision

Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010

European Medicines Agency Inspections

Community herbal monograph on Arctostaphylos uva-ursi (L.) Spreng., folium

Community herbal monograph on Pimpinella anisum L., fructus

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HAMAMELIS VIRGINIANA L., FOLIUM

Superseded. Community herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma

European Medicines Agency decision

Community herbal monograph on Panax ginseng C.A.Meyer, radix

Meeting report, September 2005

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Superseded. Community herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix. September 2010 list (MLWP)

Transcription:

1 2 3 22 May 2012 EMA/HMPC/312890/2012 Committee on Herbal Medicinal Products (HMPC) 4 5 6 7 8 Concept paper on non-pharmacopoeial reference standards for herbal substances, herbal preparations and herbal medicinal / traditional herbal medicinal Draft Discussion by HMPC Drafting Group on Quality February 2012 April 2012 Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation 22 May 2012 Start of public consultation 27 June 2012 End of consultation (deadline for comments) 15 October 2012 Comments should be provided using this template to hmpc.secretariat@ema.europa.eu Keywords HMPC; herbal medicinal ; traditional herbal medicinal ; herbal substances; herbal preparations; reference standards; primary standards; secondary standards; constituents with known therapeutic activity; active markers; analytical markers; non-pharmacopoeial reference standards 9 7 Westferry Circus Canary Wharf London E14 4HB United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union European Medicines Agency, 2012. Reproduction is authorised provided the source is acknowledged.

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 1. Introduction (background) This concept paper applies to non-pharmacopoeial reference standards for herbal substances, herbal preparations and herbal medicinal (HMPs) / traditional herbal medicinal (THMPs). The quality of herbal medicinal should be guaranteed and demonstrated in accordance with the existing requirements as set out in Annex I of Directive 2001/83/EC, as amended, with specific herbal quality guidelines such as Guideline on quality of HMPs/THMPs (EMA/CPMP/QWP/2819/00 Rev. 2) (EMA/CVMP/814/00 Rev. 2), Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and HMPs/THMPs (EMA/CPMP/QWP/2820/00 Rev. 2) (EMA/CVMP/815/00 Rev. 2), Guideline on quality of combination HMPs/THMPs (EMEA/HMPC/CHMP/CVMP/214869/2006) and, in addition, with current EU/ICH general quality guidelines for medicinal that are applicable to HMPs/THMPs. Reference standards play an essential role when ensuring and demonstrating adequate and consistent quality of herbal substances, herbal preparations and HMPs/THMPs. These reference standards may be a botanical sample of the herbal substance, a sample of the herbal preparation (e.g. extract or tincture) or a chemically defined substance e.g. a constituent with known therapeutic activity, an active marker or an analytical marker etc. In the European Pharmacopoeia (Ph. Eur.) monographs on herbal substances and herbal preparations, pharmacopoeial reference standards are described for a specific purpose and they are only demonstrated to be suitable for the use indicated. Where pharmacopoeial reference standards are available they should be used as primary standards. In cases, where pharmacopoeial reference standards are not available, non-pharmacopoeial reference standards should be established. The purpose of the proposed guideline is to identify the criteria to be taken into account when using non-pharmacopoeial reference standards and to provide guidance on the documentation needed to demonstrate that they are adequately characterised and suitable for their intended purpose. 2. Scope The concepts described in the proposed guideline will be applicable to registration applications for THMPs for human use and will also be applicable to marketing authorisation applications for HMPs for human and veterinary use. 3. Problem statement Active substances (herbal substance(s) and/or herbal preparation(s)) in HMPs consist of complex mixtures of phytochemical constituents. To ensure adequate quality control, reference standards are necessary for their identification, purity testing and assay. Existing guidelines provide only limited guidance on non-pharmacopoeial reference standards (e.g. on Specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and HMPs/THMPs ). As a result, the choice of these non-pharmacopoeial reference standards, their production and the quality documentation provided vary between applicants/manufacturers, even for similar. herbal preparations and herbal medicinal / traditional herbal medicinal EMA/HMPC/312890/2012 Page 2/5

48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 4. Discussion (on the problem statement) A non-pharmacopoeial reference standard may be a botanical sample of the herbal substance, a sample of the herbal preparation (e.g. extract or tincture) or a chemically defined substance e.g. a constituent with known therapeutic activity, an active marker or an analytical marker etc. Chemically defined substances are either commercially available or they have to be isolated and purified. However, in every case, as described in Ph. Eur. Chapter 5.12., detailed documentation on the structural elucidation and the purity should be provided, especially if the reference standard is intended for an assay. These substances can be used as primary or secondary standards. A guideline on non-pharmacopoeial reference standards should describe in detail the documentation that the applicant should provide in order to demonstrate that the reference standard is adequately characterised and meets quality standards appropriate for its intended use. 5. Recommendation As there is very little information on reference standards in the existing guidelines, the HMPC recommends the development of a respective guideline. A guideline on non-pharmacopoeial reference standards for herbal substances, herbal preparations and HMP/THMPs should describe the information to be provided in Module 3 sections 3.2.S.5. and 3.2.P.6. Reference standards or materials. This guideline shall apply to THMPs for human use and to HMPs both for human and veterinary use. 6. Timetable It is anticipated that a draft guideline could be available one year after publication of the concept paper. The draft guideline will be released for external consultation for six months. The guideline could be finalised within six months after external consultation. 7. Resource requirements for preparation The Rapporteur and Co-Rapporteur should prepare a draft guideline. Members States are invited to provide comments via their Committee and/or Working Party Members. 8. Impact assessment (anticipated) The development of this guideline on non-pharmacopoeial reference standards is expected to benefit industry. When non-pharmacopoeial reference standards need to be used, this guideline will clarify the information to be submitted in Module 3 (sections 3.2.S.5. and 3.2.P.6. Reference standards or materials ), taking account of the nature of the non-pharmacopoeial reference standard, its intended use, production, labelling and storage. This will therefore provide benefits to applicants in the preparation of their applications. The guideline is also expected to help competent authorities when assessing applications by harmonising requirements and thus enabling a more consistent approach to assessment of the documentation. herbal preparations and herbal medicinal / traditional herbal medicinal EMA/HMPC/312890/2012 Page 3/5

83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 9. Interested parties During the consultation period on the draft guideline, comments from parties concerned with the use of THMPs and HMPs will be welcome. 10. Definitions Characteristic constituents are chemically defined substances or groups of substances that are specific for a medicinal plant and can be used for identification purposes. Constituents with known therapeutic activity: are chemically defined substances or groups of substances, which are generally accepted to contribute substantially to the therapeutic activity of a herbal substance, a herbal preparation or a herbal medicinal product. Herbal medicinal : any medicinal product, exclusively containing as active substances one or more herbal substances or one or more herbal preparations, or one or more such herbal substances in combination with one or more such herbal preparations. Herbal preparations: are obtained by subjecting herbal substances to treatments such as extraction, distillation, expression, fractionation, purification, concentration or fermentation. These include comminuted or powdered herbal substances, tinctures, extracts, essential oils, expressed juices and processed exudates. Herbal substances: all mainly whole, fragmented or cut plants, plant parts, algae, fungi, lichen in an unprocessed, usually dried form but sometimes fresh. Certain exudates that have not been subjected to a specific treatment are also considered to be herbal substances. Herbal substances are precisely defined by the plant part used and the botanical name according to the binomial system (genus, species, variety and author). Impurity: (1) Any component of the herbal substance, which is not the entity defined as the herbal substance. (2) Any component of the herbal preparation/herbal medicinal product that is not the entity defined as the herbal substance/ preparation or an excipient in the herbal preparation/herbal medicinal product. Markers: are chemically defined constituents or groups of constituents of a herbal substance, a herbal preparation or a herbal medicinal product which are of interest for control purposes independent of whether they have any therapeutic activity. Markers serve to calculate the quantity of herbal substance(s) or herbal preparation(s) in the herbal medicinal product if the marker has been quantitatively determined in the herbal substance or herbal preparation. There are two categories of markers: Analytical markers are constituents or groups of constituents that serve solely for analytical purposes. Active markers are constituents or groups of constituents, which are generally accepted to contribute to the therapeutic activity. Reference standard: is a general term covering reference substances, reference preparations and reference spectra, used as a standard in an assay, an identification or a purity test. Primary standard: A standard shown to have suitable properties for the intended use, the demonstration of suitability being made without comparison to an existing standard. Secondary standard: A standard established by comparison with a primary standard. herbal preparations and herbal medicinal / traditional herbal medicinal EMA/HMPC/312890/2012 Page 4/5

122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 Specification: A list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a herbal substance/preparation or herbal medicinal product should conform to be considered acceptable for its intended use. "Conformance to specifications" means that the herbal substance/preparation and/or herbal medicinal product, when tested according to the listed analytical procedures, will meet the listed acceptance criteria. Specifications are binding quality standards that are agreed to between competent regulatory authorities and applicants. Traditional herbal medicinal : are medicinal for human use that fulfil the conditions laid down in article 16a (1) of Directive 2001/83/EC, as amended. Unidentified impurity: an impurity which is defined solely by qualitative analytical properties, (e.g., chromatographic retention time). 11. References - Guideline on quality of herbal medicinal /traditional herbal medicinal. (EMA/CPMP/QWP/2819/00 Rev. 2), (EMA/CVMP/814/00 Rev. 2). - Guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal /traditional herbal medicinal. (EMA/CPMP/QWP/2820/00 Rev. 2), (EMA/CVMP/815/00 Rev. 2). - Guideline on quality of combination herbal medicinal / traditional herbal medicinal. (EMEA/HMPC/CHMP/CVMP/214869/2006). - Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal and traditional herbal medicinal. (EMEA/HMPC/253629/2007). - European Pharmacopoeia Chapter 5.12. Reference standards. herbal preparations and herbal medicinal / traditional herbal medicinal EMA/HMPC/312890/2012 Page 5/5